Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AKRO Akero Therapeutics

盘前交易 07-22 07:54:03 EDT

26.76

-0.32

-1.18%

最高27.41	最低26.28	成交量68.70万
今开27.14	昨收27.08	日振幅4.17%
总市值18.50亿	流通市值14.65亿	总股本6,915万
成交额1,842万	换手率1.25%	流通股本5,475万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"AKRO","market":"US","secType":"STK","nameCN":"Akero Therapeutics","latestPrice":26.76,"timestamp":1721419200000,"preClose":27.08,"halted":0,"volume":686985,"delay":0,"floatShares":54751817,"shares":69151007,"eps":-3.220893,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.32,"latestTime":"07-22 07:54:03 EDT","open":27.14,"high":27.41,"low":26.28,"amount":18419114.128155,"amplitude":0.041728,"askPrice":29.85,"askSize":100,"bidPrice":25.08,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.220893,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721655000000},"adr":0,"listingDate":1561003200000,"adjPreClose":26.76,"postHourTrading":{"tag":"盘后","latestPrice":26.76,"preClose":26.76,"latestTime":"17:07 EDT","volume":58285,"amount":1559706.6,"timestamp":1721423275135},"volumeRatio":0.6113445815542717,"impliedVol":0.4617,"impliedVolPercentile":0.088},"requestUrl":"/m/hq/s/AKRO/wiki","defaultTab":"wiki","newsList":[{"id":"2442216554","title":"Akero Therapeutics, Inc.盘中异动 大幅上涨5.66%报24.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442216554","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442216554?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:31","pubTimestamp":1718199067,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时31分，Akero Therapeutics, Inc.股票出现波动，股价大幅拉升5.66%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。消息层面，截至21时31分，《沃尔夫研究首予Akero Therapeutics买入评级，目标价40美元》资讯为影响Akero Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061221310896813afb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061221310896813afb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4588","BK4139","BK4505","AKRO","BK4585"],"gpt_icon":0},{"id":"2441482270","title":"BUZZ-在礼来公司的肥胖症药物显示出对肝脏疤痕的益处后，NASH 药物开发商倒下了","url":"https://stock-news.laohu8.com/highlight/detail?id=2441482270","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441482270?lang=zh_cn&edition=full","pubTime":"2024-06-05 23:09","pubTimestamp":1717600192,"startTime":"0","endTime":"0","summary":"    6月5日 - ** NASH药物开发商Madrigal Pharmaceuticals   股价下跌约10%，报220.76美元；Akero Therapeutics   下跌3.3%，报18.58美元；89Bio   下跌约2%，报8.19美元。** 礼来  报告了其肥胖症药物的中期研究数据，该药物正在一种以前被称为NASH、现在被称为代谢功能障碍相关性脂肪性肝炎的严重脂肪肝患者中进行测试。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU2237443978.SGD","BK4533","IE00BJT1NW94.SGD","LU0079474960.USD","LU0097036916.USD","LU1280957306.USD","LU2237443622.USD","LU0114720955.EUR","LU1057294990.SGD","LU1551013425.SGD","LU0061475181.USD","LU1814569148.SGD","LU0708995401.HKD","LU2237443549.SGD","LU2491050154.USD","LU0256863811.USD","BK4007","LU0882574139.USD","LU1988902786.USD","LU1804176565.USD","LU2491049909.HKD","LU0943347566.SGD","LU0109391861.USD","ETNB","LU0820561909.HKD","AKRO","LU2468319806.SGD","LU1551013342.USD","LU0689472784.USD","LLY","IE0004445239.USD","LU0882574055.USD","IE00B1BXHZ80.USD","LU2265009873.SGD","IE00BJJMRZ35.SGD","LU1623119135.USD","LU2237443382.USD","MDGL","LU0058720904.USD","LU1712237335.SGD","IE0009355771.USD","LU0289739699.SGD","BUZZ","IE0002141913.USD","BK4534","GB00BDT5M118.USD","LU2491050071.SGD","LU2264538146.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2441279487","title":"Akero Therapeutics, Inc.盘中异动 早盘股价大跌6.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441279487","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441279487?lang=zh_cn&edition=full","pubTime":"2024-06-05 21:31","pubTimestamp":1717594276,"startTime":"0","endTime":"0","summary":"北京时间2024年06月05日21时31分，Akero Therapeutics, Inc.股票出现异动，股价快速下跌6.30%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406052131179f1cea8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406052131179f1cea8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","AKRO","BK4588","BK4585","LENZ"],"gpt_icon":0},{"id":"2439584296","title":"Akero Therapeutics, Inc.盘中异动 下午盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439584296","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439584296?lang=zh_cn&edition=full","pubTime":"2024-05-29 03:16","pubTimestamp":1716923796,"startTime":"0","endTime":"0","summary":"北京时间2024年05月29日03时16分，Akero Therapeutics, Inc.股票出现异动，股价大幅拉升5.02%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.84%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240529031636af8ab836&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240529031636af8ab836&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4585","BK4505","BK4139","AKRO","BK4588"],"gpt_icon":0},{"id":"2434868435","title":"Akero Therapeutics Inc    预计每股亏损 97 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2434868435","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434868435?lang=zh_cn&edition=full","pubTime":"2024-05-10 23:09","pubTimestamp":1715353760,"startTime":"0","endTime":"0","summary":"   * Akero Therapeutics Inc    将于5月10日公布截至2024年6月30日的财报，预计季度收入将保持不变。*    * LSEG分析师对Akero Therapeutics Inc的平均预期是每股亏损97美分。* 华尔街对 Akero Therapeutics Inc 的 12 个月目标价中位数为 50.00 美元，高于其上一次收盘价 20.80 美元。5月10日 - 以前季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","AKRO"],"gpt_icon":0},{"id":"2432908967","title":"Akero Therapeutics, Inc.盘中异动 早盘股价大涨5.23%报20.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432908967","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432908967?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:34","pubTimestamp":1714743266,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时34分，Akero Therapeutics, Inc.股票出现波动，股价急速上涨5.23%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.40%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050321342687e8578e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050321342687e8578e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","AKRO","BK4585","LENZ","BK4505"],"gpt_icon":0},{"id":"2430828675","title":"Akero Therapeutics, Inc.盘中异动 早盘股价大跌5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430828675","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430828675?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:40","pubTimestamp":1714052402,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时40分，Akero Therapeutics, Inc.股票出现波动，股价急速下挫5.75%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.31%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。该信息摘要如下：B of A Securities：重申Akero Therapeutics中性评级, 目标价30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252140027923762c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252140027923762c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","AKRO","LENZ","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2429418459","title":"B of A Securities：重申Akero Therapeutics(AKRO.US)中性评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429418459","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429418459?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:35","pubTimestamp":1713782112,"startTime":"0","endTime":"0","summary":"B of A Securities：重申Akero Therapeutics(AKRO.US)中性评级, 目标价30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221835168b45cc0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221835168b45cc0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"2421778342","title":"Akero Therapeutics, Inc.盘中异动 快速下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421778342","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2421778342?lang=zh_cn&edition=full","pubTime":"2024-03-21 00:27","pubTimestamp":1710952051,"startTime":"0","endTime":"0","summary":"北京时间2024年03月21日00时27分，Akero Therapeutics, Inc.股票出现波动，股价大幅下挫5.04%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.90%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403210027327a4dfdad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403210027327a4dfdad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","AKRO","BK4588","BK4585"],"gpt_icon":0},{"id":"2419124937","title":"资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH，竞争对手却围追堵截","url":"https://stock-news.laohu8.com/highlight/detail?id=2419124937","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419124937?lang=zh_cn&edition=full","pubTime":"2024-03-15 04:09","pubTimestamp":1710446976,"startTime":"0","endTime":"0","summary":"    路透社3月14日 - Madrigal Pharmaceuticals公司的  药物成为第一个获得监管部门批准的 ，用于治疗一种以前被称为非酒精性脂肪性肝炎的严重类型的脂肪肝，因为开发一个数十亿美元市场的竞争正在加剧。在周四获得批准之前，该公司在开发这种疾病的治疗方法方面取得了有限的成功，这种疾病与肥胖密切相关，而且正在迅速蔓延。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1623119135.USD","LU2361044949.HKD","BK4534","SG9999014559.SGD","BK4533","LU0097036916.USD","LU2237443622.USD","LU1878469433.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU1066053197.SGD","SG9999014575.USD","AKRO","IONS","LU2023250843.SGD","LU1989772923.USD","LU2361044865.SGD","LU1712237335.SGD","LU2265009873.SGD","VKTX","LU2237443549.SGD","LU2491049909.HKD","SG9999015341.SGD","LU0820561909.HKD","LU0211331839.USD","ETNB","MDGL","LU1917777945.USD","LU1551013342.USD","LLY","LU1551013425.SGD","LU2491050071.SGD","LU0114720955.EUR","SG9999001176.SGD","LU2264538146.SGD","LU2461242641.AUD","IE0009355771.USD","ALT","IE0002141913.USD","LU2361045086.USD","LU2491050154.USD","LU1066051498.USD","LU0943347566.SGD","LU1804176565.USD","MRK","LU2237443978.SGD","LU0882574055.USD","LU2237443382.USD","SG9999014880.SGD","GB00BDT5M118.USD"],"gpt_icon":0},{"id":"2419009776","title":"Akero Therapeutics, Inc.盘中异动 股价大跌5.11%报26.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419009776","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419009776?lang=zh_cn&edition=full","pubTime":"2024-03-14 21:53","pubTimestamp":1710424394,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日21时53分，Akero Therapeutics, Inc.股票出现异动，股价快速下挫5.11%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.26%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314215315791a7ca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314215315791a7ca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKRO","BK4505","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2417200459","title":"美国研究综述-树皮、Fleetcor Technologies、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2417200459","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417200459?lang=zh_cn&edition=full","pubTime":"2024-03-05 14:57","pubTimestamp":1709621845,"startTime":"0","endTime":"0","summary":"    路透社3月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Bark、Fleetcor Technologies 和特斯拉。要闻             * Bark Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入\"；将交易价从1.54美元上调至1.9美元。* Fleetcor Technologies Inc   ：贝尔德将其评级上调至 \"跑赢大盘\"。* 特斯拉  ：加拿大皇家银行将目标价从297美元上调至298美元 以下是路透社周二报道的美国公司研究报告摘要。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCCC","PCAR","LU1670628061.USD","LU1861558580.USD","BK4149","GWW","BARK","HGV","PRVA","TSLL","XPOF","UNH","PNTG","APLS","BLUE","LU0011850046.USD","APG","PAY","LU0097036916.USD","CCOI","PLNT","SWTX","GTLB","RNA","AKYA","LU1496350171.SGD","CQP","BK4097","BK4099","MGX","PDCO","HIMS","DSP","BLD","FLT","LU0310799852.SGD","AMRC","SQSP","NTRA","LU1839511570.USD","NUVL","AMPH","HSIC","COST","IE0004445015.USD","LU1720051017.SGD","TSLA","SFIX","IBP","AKRO"],"gpt_icon":0},{"id":"2417176870","title":"美国研究综述-CommScope Holding Company、Dutch Bros、Hess","url":"https://stock-news.laohu8.com/highlight/detail?id=2417176870","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417176870?lang=zh_cn&edition=full","pubTime":"2024-03-05 03:21","pubTimestamp":1709580103,"startTime":"0","endTime":"0","summary":"    路透社3月4日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 CommScope Holding Company、Dutch Bros 和 Hess。要点 * CommScope Holding Company   ：摩根大通将其股票评级从中性下调至减持  * 荷兰兄弟  ：Piper Sandler 将其评级从中性上调至增持  * Hess Corp   ：Susquehanna 将目标价从 152 美元上调至 156 美元  * Pioneer Natural Resources Co   ：苏斯克汉纳将目标价从237美元上调至246美元  * United Therapeutics Corp   ：摩根大通将目标价从294美元下调至280美元  以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPL","BRFS","ARIS","BALL","LU0979878070.USD","IE00BMPRXR70.SGD","AVGO","ACRE","AMD","BP","BLK","AHR","ABEV","BXMT","APG","IE00B894F039.SGD","AI","LU1814569148.SGD","BK4129","AEMD","AKRO","BBIO","APA","BRP","BBWI","RNAC","CELH","AZEK","AMPH","ANNX","COF","AVDX","BRSP","AMRC","BK4110","ANIP","CHE","LU0234572021.USD","BROS","BK4535","CHK","IE00BZ1G4Q59.USD","BV","GTLS","ARI","APLS","LU0965509283.SGD","AR","AHCO","BHVN"],"gpt_icon":0},{"id":"2416111226","title":"Akero脂肪性肝炎药物试验结果积极，盘前大涨20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416111226","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416111226?lang=zh_cn&edition=full","pubTime":"2024-03-04 20:20","pubTimestamp":1709554847,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Akero Therapeutics称，该公司的一项2b期研究在第96周取得了积极的初步结果，该研究评估了其主要候选产品Efruxifermin在肝硬化前代谢功能障碍相关性脂肪性肝炎、纤维化2期或3期患者中的疗效和安全性。消息发布后，Akero应声大涨，一度暴涨97.81%，截至发稿，该公司盘前涨21.54%，报33.8美元。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1081199.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK4585","BK4139","AKRO","BK4588"],"gpt_icon":1},{"id":"2416116440","title":"BUZZ-脂肪肝药物在试验中减少瘢痕形成，Akero Therapeutics公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2416116440","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416116440?lang=zh_cn&edition=full","pubTime":"2024-03-04 19:25","pubTimestamp":1709551501,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月4日 - ** 药物开发商Akero Therapeutics  股价盘前上涨89%至52.55美元** 该公司表示， (link)，其治疗MASH（一种脂肪肝）的主要实验药物在96周后减少了患者器官的瘢痕，达到了中期研究的主要目标** MASH即代谢功能障碍相关性脂肪性肝炎，约有5%的美国人患有这种疾病。** 截至上次收盘，股价在过去 12 个月中下跌了 41.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4505","AKRO","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2416116902","title":"更新版 1-Akero公司的主导药物有助于减轻脂肪肝患者的瘢痕形成","url":"https://stock-news.laohu8.com/highlight/detail?id=2416116902","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416116902?lang=zh_cn&edition=full","pubTime":"2024-03-04 19:22","pubTimestamp":1709551329,"startTime":"0","endTime":"0","summary":"     路透社3月4日 - Akero Therapeutics   周一表示，其治疗一种脂肪肝的主要实验药物在96周后有助于减少瘢痕，达到了中期研究的主要目标。96周时瘢痕的减少 率明显高于24周时的减少 率，这表明该药物能持续改善病情。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKRO","BK4588","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2416115097","title":"Akero公司的主导药物有助于改善脂肪肝患者的瘢痕形成","url":"https://stock-news.laohu8.com/highlight/detail?id=2416115097","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416115097?lang=zh_cn&edition=full","pubTime":"2024-03-04 19:09","pubTimestamp":1709550564,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月4日 - Akero Therapeutics   周一表示，其治疗一种脂肪肝的主要实验药物在96周后有助于改善患者器官的瘢痕，达到了一项中期研究的主要目标。受此消息影响，该公司股价飙升 91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4588","AKRO","BK4585"],"gpt_icon":0},{"id":"2416460876","title":"Akero Therapeutics, Inc.盘中异动 早盘股价大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416460876","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416460876?lang=zh_cn&edition=full","pubTime":"2024-03-01 22:32","pubTimestamp":1709303565,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日22时32分，Akero Therapeutics, Inc.股票出现波动，股价快速拉升5.45%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301223245861da8e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301223245861da8e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","AKRO","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2415547226","title":"Akero Therapeutics, Inc.盘中异动 大幅拉升5.64%报28.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415547226","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415547226?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:30","pubTimestamp":1709217053,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日22时30分，Akero Therapeutics, Inc.股票出现波动，股价大幅上涨5.64%。截至发稿，该股报28.77美元/股，成交量1.4626万股，换手率0.03%，振幅0.18%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402292230547a482f48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402292230547a482f48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4505","AKRO","BK4139","BK4588"],"gpt_icon":0},{"id":"2414838317","title":"Akero Therapeutics Inc盘中异动 早盘急速跳水5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414838317","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414838317?lang=zh_cn&edition=full","pubTime":"2024-02-26 22:30","pubTimestamp":1708957854,"startTime":"0","endTime":"0","summary":"北京时间2024年02月26日22时30分，Akero Therapeutics Inc股票出现波动，股价急速下挫5.17%。Akero Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.66%。Akero Therapeutics Inc公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402262230547914b207&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402262230547914b207&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4505","BK4139","AKRO","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akerotx.com","stockEarnings":[{"period":"1week","weight":0.0421},{"period":"1month","weight":0.2076},{"period":"3month","weight":0.289},{"period":"6month","weight":0.2214},{"period":"1year","weight":-0.3946},{"period":"ytd","weight":0.146}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Akero Therapeutics, Inc.于2017年1月根据特拉华州法律注册成立。他们是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的转化疗法，以及高度未满足的医疗需求。他们最初关注的是非酒精性脂肪性肝炎，或NASH，一种没有任何批准疗法的疾病。NASH是一种非酒精性脂肪性肝病（NAFLD）的严重形式，其特征在于肝脏中的炎症和纤维化，其可发展为肝硬化，肝衰竭，癌症和死亡。NASH是肝移植的主要原因。他们的主要产品候选药物AKR-001，他们正在开发作为NASH患者的潜在治疗药物，是成纤维细胞生长因子21或FGF21的类似物。FGF21是一种内源性表达的激素，可调节全身脂质，碳水化合物和蛋白质的代谢。FGF21在保护许多类型的细胞免受各种形式的压力方面也起着关键作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.018028},{"month":2,"riseRate":0.6,"avgChangeRate":0.019077},{"month":3,"riseRate":0,"avgChangeRate":-0.098995},{"month":4,"riseRate":0.4,"avgChangeRate":-0.056},{"month":5,"riseRate":0.2,"avgChangeRate":-0.02753},{"month":6,"riseRate":0.6,"avgChangeRate":0.063125},{"month":7,"riseRate":0.666667,"avgChangeRate":0.115097},{"month":8,"riseRate":0.8,"avgChangeRate":0.094367},{"month":9,"riseRate":0.4,"avgChangeRate":0.324789},{"month":10,"riseRate":0.4,"avgChangeRate":-0.135837},{"month":11,"riseRate":0.6,"avgChangeRate":0.085265},{"month":12,"riseRate":0.6,"avgChangeRate":0.118372}],"exchange":"NASDAQ","name":"Akero Therapeutics","nameEN":"Akero Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Akero Therapeutics,AKRO,Akero Therapeutics股票,Akero Therapeutics股票老虎,Akero Therapeutics股票老虎国际,Akero Therapeutics行情,Akero Therapeutics股票行情,Akero Therapeutics股价,Akero Therapeutics股市,Akero Therapeutics股票价格,Akero Therapeutics股票交易,Akero Therapeutics股票购买,Akero Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}